Functional Genomics Approach To Extend Lifespan While Preventing Age-related Cognitive Decline
Funder
National Health and Medical Research Council
Funding Amount
$772,600.00
Summary
In our ageing population, preventing age-related neurological decline is one of the central medical challenges of the 21st century. Here we use human population data obtained from people who reached 90 years of age free of any disease, or patients who suffer from dementia, combined with functional genomics studies in animals to pinpoint new genes that can be targeted to extend lifespan while preserving neurological function in these extended years of life.
In Vivo Tau Imaging In Alzheimer’s Disease And Other Dementias
Funder
National Health and Medical Research Council
Funding Amount
$538,998.00
Summary
Alteration of the normal protein tau leads to its deposition inside the brain cells leading to their death. These deposits have been well characterized and they are associated with cognitive impairment. We propose to study tau deposits in vivo in humans using positron emission tomography (PET) and assess its association with cognition and other signs of neurodegeneration
Interaction Of Amyloid-beta And Tau Pathology In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$122,592.00
Summary
Currently, over 200,000 Australians are affected by Alzheimer's disease (AD) and related forms of dementia, causing a huge socio-economic damage. To overcome the lack of effective treatments, we need to understand the underlying causes and translate them into therapy. Using state-of-the-art cell culture and genetic mouse models, I will reveal fundamental processes in AD and related dementias, and develop tailored treatments to battle these devastating disorders.
Inflammation plays both protective and damaging roles in Alzheimer’s disease (AD), so to identify a long lasting and effective treatment, it is important that we better understand the underlying processes. Our studies implicate a cytokine called interleukin-18 (IL-18) as a factor that accelerates AD pathology. Here we propose to study the mechanisms by which this cytokine alters basic cell biological functions and how these changes affect AD pathogenesis.
Investigating Interleukin-37 As A Treatment And Biomarker For Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$677,857.00
Summary
Alzheimer’s disease (AD) is the defining healthcare condition of our generation. Finding asymptomatic at risk individuals at preclinical stages will allow initiation of therapies that will either slow or, preferably, stop the progression of the disease. Herein, we will study a protein called interleukin-37 as an early biomarker and treatment for AD.
The Missing Link: MGluR5 As A Therapeutic Target For Cognitive Decline In Dementia
Funder
National Health and Medical Research Council
Funding Amount
$563,622.00
Summary
Cognitive decline is a core feature of Alzheimer’s Disease (AD), yet there is no cure or treatment. Recent evidence suggests that a protein called mGluR5 could cause brain cells to lose function, leading to memory loss. This project will investigate whether disrupting mGluR5 function can improve cognition in mice with genetic AD. Memory will be assessed in mice using innovative touchscreen tests that closely mimic the tests used in humans.
Huntington’s disease (HD) is a devastating neurodegenerative disorder which shares several features with Alzheimer’s and Parkinson’s disease (i.e. dementia-like cognitive deficits). There is currently no cure for HD. Using a mouse model of HD and a combination of relevant drugs (i.e. N-Acetylcysteine and deferiprone) targeting two distinct levels of the cascade of events leading to HD, we will slow down the progression of the disease and correct dysfunctions within the brain.
What Drives Abnormal Cerebral Activity In Secondary Generalised Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$565,809.00
Summary
Secondary Generalised epilepsy (2GE) is a severe, disabling epilepsy syndrome characterised by childhood onset frequent, treatment resistant seizures and developmental delay. Although one of the four major categories of epilepsy, it is poorly understood. This project uses combined EEG (brainwave testing) and MRI to reveal which brain areas are involved in the epileptic activity of 2GE. Advanced analysis techniques will explore which brain regions initiate 2GE epileptic activity.
Brainstem And Hypothalamic Function And Anatomy In Migraine
Funder
National Health and Medical Research Council
Funding Amount
$652,828.00
Summary
Migraine is a disabling condition characterized by mostly unilateral throbbing head pain and a range of associated neurological symptoms. The underlying mechanisms responsible for the initiation of migraine remains unknown. We aim to determine brain anatomy and activity patterns in migraineurs throughout the migraine cycle. An understanding of the mechanisms responsible for migraine will aid in better treatment development.
A Brain-based Model Of Anxiety Sensitivity In Panic Disorder
Funder
National Health and Medical Research Council
Funding Amount
$402,214.00
Summary
This project will combine advanced brain imaging and brain network modelling to better understand the neurobiology of panic disorder with relevance to its treatment.